HAEMATOLOGY AI Error Mimic human intelligence ML


estimation Model


selection Retraining Pattern recognition DL


Predictions & evaluation Test data


Final model Representation learning Future of AI and flow cytometry.22


biomarkers based on unsupervised learning methods. These discoveries may then lead to new pathways or therapeutic targets, which might advance both research and clinical applications.


Barriers and limitations The adoption of AI into flow cytometry is not without challenges. These hurdles underscore the challenges of merging cutting-edge technology with an established field.15


Data volume and infrastructure. Flow cytometry produces enormous amounts of data, especially in the analysis of high-dimensional datasets with multi- parameter fluorescence markers. The management and processing of such data demand strong computational and storage infrastructure. For most institutions, especially those with limited resources, the acquisition and maintenance of such infrastructure can be cost-prohibitive. Standardisation issues. A significant challenge in deploying AI across flow cytometry platforms is the lack of standardisation in experimental protocols, instrument calibration, and data formats. AI models trained on data from one laboratory, may not perform well on data from another due to these inconsistencies.19


Developing universally


accepted standards for data collection and processing is critical to overcoming this limitation.


Explainability of AI models. Most AI models, especially those deep learning ones, are ‘black boxes’. Although the output produced is usually accurate, how that result was reached cannot easily be understood. Such obscurity can further erode confidence in clinicians and researchers when it comes to the


36


Addressing these challenges will position AI as an even more powerful tool for transforming flow cytometry: it drives research, diagnostics, and personalised medicine.


Future directions Personalised Medicine. One of the most exciting aspects of AI in flow cytometry is its ability to advance personalised medicine. With the use of patient-specific


reliability of AI-based outputs. Regulatory obstacles. Validation of AI-enabled diagnostic tools would be quite rigorous to meet the requirements of regulatory standards, which might be time-consuming and expensive. This is particularly so in clinical applications where patient safety and accuracy of data are top priorities.20


Extensive testing and


regulatory compliance may delay the wide adoption of AI-driven systems.


Challenges and roadmap Collaboration between technology developers, healthcare providers, researchers, and regulatory bodies will be necessary to overcome challenges.11 Some strategies include: n Development of standardised protocols in such a way that the AI models can be widely applied across platforms.


n Explainable AI, which enhances the interpretability of machine-learning algorithms for making them more transparent and trustworthy.


n Investment in cost-effective solutions such as cloud-based processing to make AI more accessible to resource- limited settings.21


n Streamlining the regulatory processes by developing clear guidelines for the validation of AI-based tools.


Predicted label Feature engineering Representative High quality


Training data Modeling & feature extraction


Correct labels High diversity Minimal noise


biomarkers, AI can identify the unique cellular signatures associated with specific diseases or treatment responses. This can lead to the development of tailored therapeutic strategies that are maximally effective with minimal side effects. For example, AI might identify specific populations of immune cells to direct immunotherapy in cancer patients, making treatment more targeted and effective.24 Real-time data analysis. The advancement in computational power will facilitate real- time analysis of flow cytometry data. As it stands, the time spent processing and interpreting the data can delay clinical decisions, especially in complicated cases. AI-driven systems would allow for instant data analysis, thus providing immediate diagnostic insight. This speed of turnaround is particularly crucial in emergency settings, such as identifying sepsis or other life-threatening conditions where time counts. Integration with robotics. Combining AI with robotics will make complete automation of flow cytometry possible. The robotic systems in this case will be helpful in sample preparation, staining, and loading.16


All the data analysis


and interpretation will be handled by the AI. This ensures fewer errors, high throughput, and standardised workflows across various conditions. Increased sensitivity and rare-cell detection. AI algorithms have the ability to pick subtle patterns in data that otherwise might not be seen using traditional analysis methods. These enhanced sensitivities are specifically useful for identifying rare-cell populations, such as circulating tumour cells or minimal residual disease (MRD) in haematological malignancies.18


Early diagnosis and


monitoring abilities will thereby be improved with AI capabilities, which would result in better management of disease and improved patient outcomes.


Conclusions


Flow cytometry has long been one of the cornerstones of modern diagnostics. It can offer insight into cellular characteristics and functions at unparalleled levels. Integration with AI amplifies the scope in this regard, as data collection, analysis, and utilisation can be transformed completely. With AI, sensitivity increases, workflow accelerates, and data can be interpreted immediately, indicating a significant step toward precision diagnostics. Despite the promise, there remain challenges of high costs, data integration issues, and regulatory compliance, which must be addressed. This new technology offers faster and more accurate diagnostics, the tailoring of treatments to specific patients,


APRIL 2025 WWW.PATHOLOGYINPRACTICE.COM


True label


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56